Taking progestogens during high-risk pregnancy could reduce preterm birth

Reviewed by Emily Henderson, B.Sc.Mar 31 2021

Taking progestogens - steroid hormones - during pregnancy could reduce the risk of preterm birth in high-risk single baby pregnancies, research has shown.

Although these compounds have been in use for some time, results of individual clinical trials investigating their effectiveness in preventing preterm birth have been conflicting, and so further evaluation of the research evidence was needed.

University of York researchers led the Evaluating Progestogens for Prevention of Preterm Birth International Collaborative (EPPPIC) project, a systematic review which brought together and re-analysed datasets from 31 clinical trials of progestogens, including more than 11,000 women and 16,000 babies worldwide.

Babies born preterm are at greater risk, of health problems during infancy and of death during their first year. It is therefore essential to have reliable information about how well these interventions work, and for this we need systematic and rigorous evaluation of large amounts of data.

We hope that our findings will help inform shared decision-making between clinicians and expectant mothers who are considered at high-risk of preterm birth."

Professor Lesley Stewart, Project Principal Investigator and Director, University of York's Centre for Reviews and Dissemination

Data was obtained from trials of vaginal progesterone given as a gel or pessary, and from trials of 17-OHPC, given as an injection. The project looked separately at trial data from twin and triplet pregnancies. It is the first meta-analysis using raw data from individual pregnancies of 17-OHPC in single baby pregnancies and the first to examine both compounds together.

Both vaginal progesterone and 17-OHPC reduced the risk of preterm birth before 34 weeks for high-risk single baby pregnancies - mostly for women who had experienced a previous preterm birth or had a short cervix in their current pregnancy.

There was a consistent benefit for other outcomes including fetal and baby deaths and serious neonatal complications, including infection and lung and eye problems.

In contrast, analysis showed no evidence that either vaginal progesterone or 17-OHPC was useful for twin or triplet pregnancies with no other risk factors.

Professor Zarko Alfirevic, Coordinating Editor of Cochrane Pregnancy and Childbirth and member of the EPPPIC Secretariat, said: "Consistency of the results across so many different trials is quite remarkable and should be very reassuring to clinicians, but even more importantly to pregnant women and their families."

The study, published in Lancet, is funded through a Patient-Centered Outcomes Research Institute^® award.